Bcell Design invests €400,000 to support its commercial expansion.

On October 26, 2026, Aton Group announced that Bcell Design, a company specializing in monoclonal antibodies, raised €400,000 through convertible bonds from its existing investors. This investment will support marketing and commercial expansion, both in France and internationally.

The funds will support team expansion and marketing development. With three patented technology platforms and a catalog of 80 antibodies, the company is targeting in vitro diagnostics, serology, and the biopharmaceutical industry. Four key markets—Europe, China, Canada, and India—are being targeted to strengthen its international presence.

Aton Group, the majority shareholder of Inoviem Scientific, which itself holds shares in Bcell Design, believes this investment is a sign of confidence in its commercial future. The goal is to convert current trials into orders and to grow international revenue.